Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

GOVARDHANAN NAGAIAH

Allopathic & Osteopathic Physicians Internal Medicine Hematology & Oncology

NPI
1386736585
CMS profile
1171310
Location
GOODYEAR, AZ

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2022 · Entire year

$35,412.30

181 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2022 · entire year · sorted by reported total

By paying entity

PY2022 · entire year · sorted by reported total

Paying entityAmountRecords
Sobi, Inc $21,088.58 13
Regeneron Healthcare Solutions, Inc. $7,668.71 6
ABBVIE INC. $2,139.87 5
PFIZER INC. $1,593.74 6
E.R. Squibb & Sons, L.L.C. $331.27 17
Genentech USA, Inc. $288.86 14
Celgene Corporation $266.74 15
Seagen Inc. $174.76 9
GENZYME CORPORATION $135.32 7
Amgen Inc. $128.02 9
Roche Diagnostics Corporation $122.53 1
Janssen Biotech, Inc. $92.32 5
Incyte Corporation $85.01 5
Merck Sharp & Dohme LLC $82.34 4
Novartis Pharmaceuticals Corporation $70.40 4
Daiichi Sankyo Inc. $70.17 3
EMD Serono, Inc. $67.19 4
AstraZeneca Pharmaceuticals LP $66.12 3
Karyopharm Therapeutics Inc. $65.75 3
Boehringer Ingelheim Pharmaceuticals, Inc. $65.54 3
G1 Therapeutics, Inc. $51.84 3
Kyowa Kirin, Inc. $49.32 3
Blueprint Medicines Corporation $43.46 2
Heron Therapeutics, Inc. $42.72 2
ARRAY BIOPHARMA INC $35.06 2
EISAI INC. $34.33 2
Lilly USA, LLC $33.63 2
Exelixis Inc. $33.32 2
Pharmacosmos Therapeutics Inc. $32.91 2
GlaxoSmithKline, LLC. $30.52 2
Alexion Pharmaceuticals, Inc. $28.71 2
AVEO Pharmaceuticals, Inc. $27.79 2
Bayer HealthCare Pharmaceuticals Inc. $23.91 1
SERVIER PHARMACEUTICALS LLC $23.82 1
Gilead Sciences, Inc. $23.57 1
AMAG Pharmaceuticals, Inc. $23.45 1
Puma Biotechnology, Inc. $22.98 1
Pharmacyclics LLC, an AbbVie Company $22.80 1
Clovis Oncology, Inc. $20.74 1
CTI BioPharma Corp. $20.28 1
ADC Therapeutics America, Inc. $20.00 1
Coherus Biosciences Inc. $18.33 1
Myovant Sciences Inc. $18.33 1
Epizyme, Inc., $18.16 1
Boston Scientific Corporation $17.23 1
Rigel Pharmaceuticals, Inc. $17.02 1
Sun Pharmaceutical Industries Inc. $16.87 1
JAZZ PHARMACEUTICALS INC. $16.26 1
BeiGene USA, Inc. $15.73 1
Takeda Pharmaceuticals U.S.A., Inc. $13.09 1
Kite Pharma, Inc. $12.88 1

Page 4 of 4; records 151–181 of 181 matching records. This page contains 31 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

GOVARDHANAN NAGAIAH

NPI 1386736585 · CMS profile ID 1171310

Allopathic & Osteopathic Physicians / Internal Medicine / Hematology & Oncology

GOODYEAR, AZ

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 4 of 4; records 151–181 of 181 matching records. This page contains 31 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1386736585?year=2022&recipient=provider&page=4#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
GOVARDHANAN NAGAIAH, NPI 1386736585, CMS profile ID 1171310. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 4 of 4; records 151–181 of 181 matching records. This page contains 31 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1386736585?year=2022&recipient=provider&page=4#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
APA 7
IndustryPayments. (2026). GOVARDHANAN NAGAIAH, NPI 1386736585, CMS profile ID 1171310. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 4 of 4; records 151–181 of 181 matching records. This page contains 31 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1386736585?year=2022&recipient=provider&page=4#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
Bluebook
GOVARDHANAN NAGAIAH, NPI 1386736585, CMS profile ID 1171310, IndustryPayments, General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 4 of 4; records 151–181 of 181 matching records. This page contains 31 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c. https://industrypayments.org/provider/npi-1386736585?year=2022&recipient=provider&page=4#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2022

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2022 · Physicians and non-physician practitioners · CMS publication 2026-06-30

181 matching records · $35,412.30 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 181 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 151–181 of 181.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Amgen Inc. $9.3103/23/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 939853269 CMS
EISAI INC. $19.4703/22/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 908039379 CMS
G1 Therapeutics, Inc. $15.1303/16/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 954036257 CMS
GENZYME CORPORATION $21.9003/15/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 938902651 CMS
AVEO Pharmaceuticals, Inc. $12.6903/14/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 950104169 CMS
AMAG Pharmaceuticals, Inc. $23.4503/11/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 953401849 CMS
ARRAY BIOPHARMA INC $14.8403/10/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 949098955 CMS
E.R. Squibb & Sons, L.L.C. $3.2203/07/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 932602887 CMS
E.R. Squibb & Sons, L.L.C. $16.1003/07/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 932602889 CMS
E.R. Squibb & Sons, L.L.C. $16.1203/04/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 932602883 CMS
E.R. Squibb & Sons, L.L.C. $3.2203/04/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 932602885 CMS
Seagen Inc. $11.7203/04/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 904092491 CMS
Sobi, Inc $70.1303/04/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 940380711 CMS
Sobi, Inc $3,737.5003/04/2022 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 940380713 CMS
Pharmacosmos Therapeutics Inc. $16.0503/03/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 959144887 CMS
E.R. Squibb & Sons, L.L.C. $22.8503/01/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 932602875 CMS
Blueprint Medicines Corporation $20.0002/28/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 958937807 CMS
Seagen Inc. $18.7902/25/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 904092481 CMS
Seagen Inc. $22.2702/23/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 904092479 CMS
Genentech USA, Inc. $15.4202/21/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 950798769 CMS
Celgene Corporation $22.1402/16/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 932602735 CMS
BeiGene USA, Inc. $15.7302/15/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 940793731 CMS
GENZYME CORPORATION $10.4302/14/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 938902643 CMS
ABBVIE INC. $1,650.0002/11/2022 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891228151 CMS
Genentech USA, Inc. $19.6902/11/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 950801755 CMS
E.R. Squibb & Sons, L.L.C. $17.2802/10/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 932602733 CMS
EMD Serono, Inc. $18.5902/09/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 941490759 CMS
Alexion Pharmaceuticals, Inc. $13.3502/08/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 915612581 CMS
Kyowa Kirin, Inc. $12.8902/08/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 905046257 CMS
Sobi, Inc $1,150.0001/25/2022 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 940380715 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $17.7001/05/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 887533813 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $66,781.92 249
PY2020 $30,781.63 100
PY2021 $37,961.35 193
PY2022 $35,412.30 181
PY2023 $37,048.78 220
PY2024 $9,094.03 217
PY2025 $4,699.74 133

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $211,255.00 7
PY2024 Principal investigator $197,185.15 38
PY2023 Principal investigator $150,571.76 44
PY2022 Principal investigator $310,184.42 140
PY2021 Principal investigator $166,559.34 50
PY2020 Principal investigator $99,527.66 56
PY2019 Recipient $18,403.00 1
PY2019 Principal investigator $192,629.40 43

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

7 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 AstraZeneca Pharmaceuticals LP $62,441.52 05/30/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE
A Phase III, Open-label, Randomised Study of Neoadjuvant Datopotamab Deruxtecan (Dato DXd) Plus Durvalumab Followed by Adjuvant Durvalumab With or Without Chemotherapy Versus Neoadjuvant Pembrolizumab Plus Chemotherapy Followed by Adjuvant Pembrolizumab With or Without Chemotherapy for the Treatment of Adult Patients with Untreated Triple-Negative or Hormone Receptor low/HER2-negative Breast Cancer (TROPION Breast04) No dispute reported 06/30/2026 1185539469
Principal investigator 1 AstraZeneca Pharmaceuticals LP $77,897.68 04/30/2025 Non-covered Recipient Entity
ARIZONA ONCOLOGY
A Phase III, Open-label, Randomised Study of Neoadjuvant Datopotamab Deruxtecan (Dato DXd) Plus Durvalumab Followed by Adjuvant Durvalumab With or Without Chemotherapy Versus Neoadjuvant Pembrolizumab Plus Chemotherapy Followed by Adjuvant Pembrolizumab With or Without Chemotherapy for the Treatment of Adult Patients with Untreated Triple-Negative or Hormone Receptor low/HER2-negative Breast Cancer (TROPION Breast04) No dispute reported 06/30/2026 1185539467
Principal investigator 1 TOLMAR, INC. $1,200.00 04/11/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH, LLC
TOL2506A No dispute reported 06/30/2026 1237321475
Principal investigator 1 AstraZeneca Pharmaceuticals LP $55,823.80 02/07/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase III, Open-label, Randomised Study of Neoadjuvant Datopotamab Deruxtecan (Dato DXd) Plus Durvalumab Followed by Adjuvant Durvalumab With or Without Chemotherapy Versus Neoadjuvant Pembrolizumab Plus Chemotherapy Followed by Adjuvant Pembrolizumab With or Without Chemotherapy for the Treatment of Adult Patients with Untreated Triple-Negative or Hormone Receptor low/HER2-negative Breast Cancer (TROPION Breast04) No dispute reported 06/30/2026 1185539465
Principal investigator 1 AstraZeneca Pharmaceuticals LP $510.00 01/15/2025 Non-covered Recipient Entity
TMC HEALTH CANCER CENTER WILMOT
A Phase 3 Open-label, Randomised Study of Datopotamab Deruxtecan?(DatoDXd) With or Without Durvalumab Versus Investigators Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Who Have Residual Invasive Disease in the Breast and/or Axillary Lymph Nodes at Surgical Resection Following Neoadjuvant Systemic Therapy No dispute reported 06/30/2026 1185539463
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $382.00 01/07/2025 Non-covered Recipient Entity
Us Oncology Res Llc
Randomized, Open-Label, Phase 3 Trial of Nivolumab plus Ipilimumab or Nivolumab plus Platinum-Doublet Chemotherapy versus Platinum-Doublet Chemotherapy in Early Stage Non Small Cell Lung Cancer No dispute reported 06/30/2026 1235992205
Principal investigator 1 AstraZeneca Pharmaceuticals LP $13,000.00 01/03/2025 Non-covered Recipient Entity
THE US ONCOLOGY NETWORK
A Phase 3 Open-label, Randomised Study of Datopotamab Deruxtecan?(DatoDXd) With or Without Durvalumab Versus Investigators Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Who Have Residual Invasive Disease in the Breast and/or Axillary Lymph Nodes at Surgical Resection Following Neoadjuvant Systemic Therapy No dispute reported 06/30/2026 1185539471